A recent study suggests that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who halt conventional diet and exercise programs.
Findings released in a prominent health publication points out that while obese individuals can lose about a fifth of their body weight while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month once they quit.
"Users purchasing such treatments must be aware of the risk of fast rebound weight gain when the medication concludes," cautioned expert Dr. Susan Jebb.
That rate of recovery means a reversion to starting weight within about 18 months.
Comparing Treatments
The study, which reviewed dozens of trials involving over 9,000 of patients, compared the outcomes of these new drugs with older methods.
Researchers emphasize that individuals who lose weight through lifestyle changes alone usually have a more gradual creep back—approximately 0.1 kg a month—once they finish.
Explaining the Fast Regain
Nutrition scientists suggest the mechanism of the injections is key to understanding the amplified weight return.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production might result in the body to produce less of its own natural hormone, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this hormone supplement results in hunger is no longer kept in check, making excessive eating a significant risk."
An Ongoing Condition?
Medical guidelines recommend the jabs for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
Professionals contend that, due to the significant potential of relapse, the therapy is often long-term.
This perspective is supported by pharmaceutical companies, who state that the results "highlight the persistent nature of obesity," akin to managing diseases like high blood pressure.
Patient Accounts
Users who have stopped the jabs report a powerful return of hunger.
"I experienced something activating and I was suddenly starving," said one woman.
This difficulty is compounded if patients have not developed permanent lifestyle or habit changes during treatment.
Significant Interest
Figures indicate that a significant number of people in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Adoption is higher among women than men.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
In conclusion, researchers emphasize that while the jabs are potent agents for shedding pounds, they are not a magic fix and maintained weight loss relies on integrated lifestyle changes.
